Summary 2-(4-Aminophenyl)benzothiazole molecules substituted in the 3 position of the phenyl ring with a halogen atom or methyl moiety comprise a group of compounds that potently inhibit specific human ovarian carcinoma cell lines. G150 values fall within the nm range. Inhibition is highly selective -whereas the G150 value in IGROV1 cells consistently lies at < 10 nM, SK-OV-3 presents G150 values > 10jIM. Biphasic dose-response relationships were observed in sensitive cell lines after 48-h drug exposure. COMPARE analyses revealed the very similar profiles of anti-tumour activity of 3-substituted benzothiazoles and 5-(4-dimethylaminophenylazo)quinoline, with Pearson correlation coefficients > 0.65. Anti-tumour activity extended to preliminary in vivo tests. The growth of OVCAR-3 cells in polyvinylidene fluoride (PVDF) hollow fibres implanted in the peritoneal cavity of mice was inhibited by more than 50% after intraperitoneal (i.p
2-(4-Aminophenyl)benzothiazole (CJM 126,  Figure 1 ) was originally prepared as a synthetic intermediate within a programme to design potential tyrosine kinase inhibitors modelled on structural comparisons with the flavone quercetin and isoflavone genistein (Yates et al, 1991; Stevens et al, 1994) . It was found to elicit potent inhibitory effects against breast cancer cell lines in vitro, yielding biphasic dose-response profiles (Shi et al, 1996) . Numerous analogues were synthesized and their biological activity examined. Replacement of the sulphur atom in the heterocyclic nucleus to generate benzoxazole or benzimidazole congeners had a dyschemotherapeutic effect. In contrast, substitution at position 3 of the phenyl ring with a halogen atom or a methyl group significantly enhanced potency (Shi et al, 1996) . GI50 values within the pM range were obtained in human breast carcinoma cell lines including MCF-7 oestrogen receptor-positive (ER+) and MDA 468 oestrogen receptor-negative (ER-) cell lines. In contrast, GI50 values > 30 gm were obtained when activity of the same compounds was examined in PC3 and DU 145 human prostate cell lines (Bradshaw et al, 1998) .
Anti-tumour activity extended to breast xenograft models with ER+ (MCF-7 and BO) and ER-(MT-1, MT-3 and MaTu) human tumours grown in nude mice responding to treatment with 2-(4-amino-3-methylphenyl)benzothiazole, as well as 2-(4-amino-3-iodophenyl)benzothiazole retarding the growth of MCF-7, 3366 (ER+) and MaTu (ER-) tumour xenografts (Shi et al, 1996) .
Such promising preliminary results led to wider investigations and compounds were forwarded to the National Cancer Institute, where a more comprehensive anti-tumour evaluation proceeded.
-In this paper, we describe the effects of benzothiazole molecules on human ovarian tumour growth in vitro and in vivo and 5-(4-dimethylaminophenylazo)quinoline on human ovarian tumour growth in vitro. The order of benzothiazole molecules discussed is as follows: unsubstituted 2-(4-aminophenyl)benzothiazole (CJM 126) ; molecules substituted with a halogen species at position 3 of the phenyl ring (DF 129, DF 209, DF 229) ; methyl substituted benzothiazole (DF 203) ; and further analogues in ascending DF numerical sequence (DF 180, DF 219, DF 221, DF 226).
MATERIALS AND METHODS Drugs 2-(4-Aminophenyl)benzothiazole (CJM 126) , 2-(4-amino-3-iodophenyl)benzothiazole (DF 129) , 2-(4-amino-3-bromophenyl) benzothiazole (DF 209), 2-(4-amino-3-chlorophenyl)benzothiazole (DF 229), 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) , 2-(N-chloroacetylaminophenyl)benzothiazole (DF 180) , 2-(4-amino-3-iodophenyl)-6-methylbenzothiazole (DF 219) , 2-(4-amino-3,5-dibromophenyl)benzothiazole (DF 221) and 2-(4-amino-3,5-dichlorophenyl)benzothiazole (DF 226) were synthesized according to published methods (Shi et al, 1996) . 421 Ovarian cell lines and in vitro evaluation of growth inhibitory effects   The activity of CJM 126, DF 129, DF 209, DF 229, DF 203, DF  180, DF 219, DF 221, DF 226 and NSC 680467 was examined in   six ovarian cell lines (IGROV1, OVCAR-3, OVCAR-4, OVCAR-5,  OVCAR-8 and SK-OV-3) in the laboratories of the NCI, Bethesda, MD, USA. The protocol adopted has been described in detail previously (Boyd, 1989; Monks et al, 1991 Monks et al, , 1997 (Hamburger and Salmon, 1977 N,,N 5-(4-Dimethylaminophenylazo)quinoline (NSC 680467) Figure 1 Structures of 2-(4-aminophenyl)benzothiazoles and 5-(4-dimethylaminophenylazo)quinoline (NSC 680467) cultures were incubated for 7, 8 and 9 days respectively. Colony growth was monitored using an inverted microscope. Counts were performed using an automatic image analysis system (OMNICON FAS IV, Biosys). Inhibition of colony formation was represented as the ratio of treated to control colony number (% T/C), and drug concentrations necessary to inhibit colony formation by 50% (GI50, T/C 50%), 70% (GI70, T/C 30%) and 90% (GI90, T/C 10%)
were determined. Assays were considered evaluable if: the mean number of colonies (diameter > 50 jim) was 20 or more; 1000 jig ml-' 5-fluorouracil (5-FU) (positive reference compound) effected colony survival by < 30%; and the coefficient of variation in the control group was < 50%.
COMPARE analysis
COMPARE is the computerized pattern-recognition algorithm used in evaluation of data generated by the NCI screen. It is a method of determining and expressing the degree of similarity, or lack thereof, of mean graph profiles generated on compounds. The response profile fingerprints of DF 129, DF 209, DF 229, DF 203 and NSC 680467 were used as 'seeds' to probe other mean graph databases to examine whether any closely matching profiles exist. Compounds matched by mean graph patterns frequently share related biochemical mechanisms of action (Weinstein et al, 1997) .
In vivo evaluation of activity
The Biological Testing Branch of the Developmental Therapeutics Program (NCI) has adopted the hollow-fibre assay as a preliminary compound (two doses) daily for 4 days. Six control mice received compound vehicle only. The fibre cultures were collected 24 h after the final treatment. Viable cell mass was determined using the formazan dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) conversion assay and the ratio of treated to control tumour volumes (% T/C) calculated.
The response of early-stage s.c. OVCAR-3 ovarian tumour xenografts to DF 203 was examined by the NCI after selection of this compound for further study in the Developmental Therapeutics Programme. Tumour in the form of cell suspension was implanted s.c. into pathogen-free immunodeficient athymic female nude mice on experimental day 0. In addition to control and test agent-treated groups (n = 6), titration groups were included to establish tumour doubling time. A total of three treatments were administered i.p. on days 8, 12 and 16. Vehicle was 0.1 ml per 10 g of body weight saline plus Tween 80, 0.05%; control animals received 10% dimethyl sulphoxide (DMSO) plus saline. Growth delay was determined and expressed as a percentage by which the treated-group median weight was delayed in achieving 1 g compared with that of controls.
RESULTS
In vitro evaluation of anti-tumour activity CJM 126 was inactive in the NCI ovarian panel. GI50 values > 50 gM were obtained (Table 1) .
Potent yet highly selective inhibition of ovarian cell lines was observed after a 48-h exposure to DF 129, DF 209, DF 229 and DF 203 (Figure 2 ). Whereas IGROVI, OVCAR-3 or OVCAR-5 were sensitive, OVCAR-8 or SK-OV-3 cell lines were universally resistant to the growth-inhibitory properties of these compounds. GI50 values beyond the concentration range adopted by the NCI were seen: < 10 nm for IGROVI and > 100 gM for SK-OV-3 cultures after exposure to DF 209 or DF 229, a differential greater than four orders of magnitude (Table 1) . Indeed, GI90 values < 10 nm were obtained in the IGROVI cell line (n = 3) and, at concentrations of British Journal of Cancer (1998) 78(4) Corresponding GI50 values are given in Table 2 Control 0. growth potential associated with 48-h exposure to 10 gM and 100 gM drug ( Figure 2 ) was essentially abolished after 6-day incubations (Figure 3) . In OVCAR-5 populations, potency was significantly enhanced and GI50 values < 10 nm were obtained after 6-day treatment with DF 209 and DF 229. However, the biphasic trend persisted atnd was particularly evident after challenge with DF 129 and DF 203. Figure 4 illustrates clearly the selective nature of growth inhibition within the ovarian subpanel.
Introduction of a methyl group at position 6 of the benzothiazole ring of DF 129 (DF 219) and dibromo or dichloro substitution in position 3 and 5 of the phenyl ring to give DF 221 and DF 226 resulted in diminished potency and reduced cell line selectivity (Table 1) . Biphasic responses were still encountered but shifted such that the cell nadir occurred at 10 gM.
Consistent potency against the NCI ovarian panel was seen after challenge for 48 h with DF 180. Low ,UM GI50 values were determined (Table 1) . Steep gradients representing fall in cell viabilities were seen between concentrations differing by only one order of magnitude: for example, growth of OVCAR-3 cells treated with 1 ,UM DF 180 was 87% that of control, yet 10 JM not only completely inhibited cell growth but reduced viable cell number to 58% that of initial seeding density (Figure 2) .
The selectivity associated with DF 129-, DF 209-, DF 229-and DF 203-induced growth inhibition compared with the general toxic nature of DF 180 has been confirmed in other human-derived ovarian cell lines ( Table 2) .
The cell line OAW 42 was at least 540, 280 and 80 times more sensitive than D13 to DF 129, DF 229 and DF 203 respectively. DF 229 was the most potent agent, eliciting GI50 values < 0.1 JIM (Table 2 ). The A431 human epidermoid cell line was used as a reference line for epidermal growth factor (EGF)-related tyrosine kinase activity and gave GI50 values > 24 JM in response to challenge with DF 229 (result not shown). Colony formation of xenograft 1023 ovarian cells exposed to 0.44 gM (100 ng ml-') CJM 126 was inhibited by 24%, whereas 4.42 tM inhibited clonal growth by only 8% (GI50 > 44.25 gM, (Table 3) .
A similar profile of anti-tumour activity was demonstrated for NSC 680467 after 48-h incubation, which reflected the selectivity exhibited by substituted benzothiazoles (Table 1) . Biphasic dose-response relationships were seen in sensitive IGROV1 cells (GI50 15 nM) and OVCAR-5 cells (GI50 0.68 gM), but cell numbers did not descend below the initial seeding densities. OVCAR-8 cells were refractory to growth inhibition (GI50 > 100 gM) (Figure 2 ).
In vivo assessment of ovarian anti-tumour activity Hollow-fibre assays DF 209 Whereas % T/C exceeded 100% in OVCAR-3 cells implanted s.c., exposed to DF 209, i.p. implanted tumour cells responded to treatment. Inhibition was dose dependent: 27% and 65% reduction in tumour cell mass followed treatment with 100 and 150 mg kg-' respectively. Similarly, only the growth of OVCAR-5 cells implanted i.p. was retarded (150 mg kg-') ( Table 4) . DF 229 Significant growth retardation of OVCAR-3 cultures within the peritoneum was seen (55%) after treatment with 100 mg kg-'. However, the higher dose of 150 mg kg-' induced only 22% inhibition. OVCAR-3 cells implanted s.c. were inhibited by 24% and 20% by 100 and 150 mg kg-' DF 229 respectively (Table 4) . Injection of DF 229 had negligible effect on the growth of OVCAR-5 tumour cells implanted s.c. The growth of tumour cells implanted i.p. was inhibited by 25% and 36% after treatment with 100 and 150 mg kg-' respectively. DF 203 In the hollow-fibre in vivo model, DF 203 was the most effective of the benzothiazole anti-tumour agents tested to date. At concentrations of 6.7 and 10 mg kg-', significant inhibition of OVCAR-3 cell growth was observed at both tumour implantation sites: 45 < % T/C < 51. Inhibition of i.p. implanted OVCAR-5 cells exceeded growth inhibition at s.c. sites, with 50% and 77% inhibition of i.p. tumour growth after treatment with 6.7 and 10 mg kg-' DF 203 respectively (Table 4) . Growth inhibition of s.c. OVCAR-3 xenograft tumours was detected after i.p. administration of 11.2, 16.8 and 25 mg kg-' DF 203. However, only at the lowest dose was % T/C < 50% ( Figure  7) . The relationship between growth delay and DF 203 concentration was inverse. The initial mean doubling time of control tumours was 2.9 days. A maximum-tolerated dose was not (Tables I and 2 ) in addition to breast (Shi et al, 1996) (Bradshaw et al, 1998 (Bradshaw et al, 1998) . Therefore, a shared mechanism(s) of resistance is implied.
We have observed rapid uptake and metabolism of benzothiazoles by sensitive cells in culture: acetylated and oxidized biotransformation products have been recovered. In contrast, prostate-derived tumour cells that possess intrinsic resistance to these compounds show no net benzothiazole loss from surrounding medium and only negligible acetylation (Chua et Within the human ovarian panel, the N-chloroacetylated amine DF 180 failed to show any specificity in its profile of anti-tumour activity (Table 1) . These observations are supported by data generated from the complete NCI tumour panel of 60 human-derived cell lines in addition to clonogenic work.
At a concentration of 10 ,g ml-', DF 180 inhibited colony formation of 18 of 22 tumours by > 70%, whereas none of the 22 tumours, which included lung, melanoma, gastric and bladder cell lines, demonstrated this level of inhibition at 10 ng ml'. Compare these data with corresponding figures for DF 203: at 10 ,g ml' in only 2 of 22 tumours was clonogenic growth inhibition > 70%; equally at 10 ng ml', in the same two tumours only, % T/C was < 30%. This illustrates the selectivity (in this case, the two responsive tumours were of breast origin) and potency of DF 203 compared with the general toxicity elicited by DF 180.
The NCI disease-oriented strategy for drug discovery is based on the hypothesis that selective activity in vitro against cancer cell lines from a specific organ may predict selective activity against corresponding tumours in vivo. Significant anti-tumour activity of DF 129, DF 203 (Shi et al, 1996) and DF 229 in breast xenograft models including MCF-7 has been demonstrated. Recently potent anti-tumour activity of 5,4'-diaminoflavone derivatives, structurally related to 2-(4-aminophenyl)benzothiazoles, has been demonstrated in MCF-7 cells in vitro and in vivo (Akama et al, 1997) . We may speculate that certain pharmacological mechanisms of action may be shared. Intriguingly, two human ovarian cell lines (A2780 and OVCAR-3) were also sensitive to the growthinhibitory properties of 5,4'-diamino-6,8,3'-trifluoroflavone.
Specificity extended to in vivo tests. The two ovarian cell lines routinely selected for implantation after culture in PVDF hollow fibres were the only cell lines whose growth was inhibited after exposure to DF 209, DF 229 and DF 203. DF 203 was significantly more toxic; the maximum-tolerated doses of DF 209, DF 229 and DF 180 were ten times that of DF 203. Indeed, DF 203, which, of the 3-substituted benzothiazoles, was the least powerful inhibitor of growth in vitro, proved the most effective agent tested in retarding the growth of OVCAR-3 and OVCAR-5 tumour cells implanted both i.p. and s.c. in hollow-fibre in vivo experiments. Evidence of the biphasic dose response observed in in vitro assays was marked in i.p. transplanted OVCAR-3 tumours exposed to DF 229 (Table 3) . DF 180, as in vitro data would predict, failed to demonstrate selectivity.
The growth delay encountered after treatment of s.c. OVCAR-3 xenograft tumours with DF 203 was not significant. Delivery via the i.p. route may inefficiently reach s.c. sites. In support of this theory, growth inhibition of cells cultured in hollow fibres and implanted i.p. exceeded anti-tumour activity at s.c. sites, after exposure to DF 209 and DF 229. The inverse relationship observed between DF 203 concentration and % T/C appears to reflect in vitro observations. Metabolic routes of anti-tumour benzothiazoles in vivo and in vitro are being investigated.
Finally, the promising anti-tumour potential of these novel benzothiazole molecules, ease of syntheses (Stevens et al 1995; Shi et al, 1996) , high yields, simple structures and compound stability appear to justify further preclinical development. ABBREVIATIONS NCI, National Cancer Institute; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; GI50, GI70 and GI90 concentrations at which 50%, 70% and 90% inhibition were encountered.
